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Abstract
Background: The transmissible spongiform encephalopathies (TSEs), otherwise known as the
prion diseases, occur following the conversion of the normal cellular prion protein (PrPC) to an
alternatively folded isoform (PrPSc). The accumulation of PrPSc within the brain leads to
neurodegeneration through an unidentified mechanism. Since many neurodegenerative disorders
including prion, Parkinson's and Alzheimer's diseases may be modified by cholesterol synthesis
inhibitors, the effects of prion infection on the cholesterol balance within neuronal cells were
examined.
Results: We report the novel observation that prion infection altered the membrane composition
and significantly increased total cholesterol levels in two neuronal cell lines (ScGT1 and ScN2a
cells). There was a significant correlation between the concentration of free cholesterol in ScGT1
cells and the amounts of PrPSc. This increase was entirely a result of increased amounts of free
cholesterol, as prion infection reduced the amounts of cholesterol esters in cells. These effects
were reproduced in primary cortical neurons by the addition of partially purified PrPSc, but not by
PrPC. Crucially, the effects of prion infection were not a result of increased cholesterol synthesis.
Stimulating cholesterol synthesis via the addition of mevalonate, or adding exogenous cholesterol,
had the opposite effect to prion infection on the cholesterol balance. It did not affect the amounts
of free cholesterol within neurons; rather, it significantly increased the amounts of cholesterol
esters. Immunoprecipitation studies have shown that cytoplasmic phospholipase A2 (cPLA2) co-
precipitated with PrPSc in ScGT1 cells. Furthermore, prion infection greatly increased both the
phosphorylation of cPLA2 and prostaglandin E2 production.
Conclusion: Prion infection, or the addition of PrPSc, increased the free cholesterol content of
cells, a process that could not be replicated by the stimulation of cholesterol synthesis. The
presence of PrPSc increased solubilisation of free cholesterol in cell membranes and affected their
function. It increased activation of the PLA2 pathway, previously implicated in PrPSc formation and
in PrPSc-mediated neurotoxicity. These observations suggest that the neuropathogenesis of prion
diseases results from PrPSc altering cholesterol-sensitive processes. Furthermore, they raise the
possibility that disturbances in membrane cholesterol are major triggering events in
neurodegenerative diseases.
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Cholesterol levels within the brain may affect the patho-
genesis of some neurodegenerative diseases including
Alzheimer's and Parkinson's diseases and multiple sclero-
sis [1,2]. Neuronal cholesterol levels are also thought to
affect the progression of the transmissible spongiform
encephalopathies (TSEs), otherwise known as prion dis-
eases [3]. These diseases are associated with the conver-
sion of the normal cellular prion protein (PrPC) to an
alternatively folded isoform (PrPSc) [4]. The accumulation
of PrPSc is closely associated with the main pathological
features of TSEs: the spongiform degeneration of the
brain, synaptic alterations, glial cell activation and exten-
sive neuronal loss [5,6]. While a recent study reported that
prion infection in vivo was associated with changes in
brain cholesterol levels [7], the change in cholesterol reg-
ulation in neurons following prion infection has not been
characterised extensively. Furthermore, because the brain
is composed of diverse cell types, it is possible that
changes in the cholesterol content of neurons may be
obscured in mixed cell populations or whole brain stud-
ies. To reduce the problem of cell heterogeneity, the effects
of prion infection on two neuronal cell lines were exam-
ined. We report that prion infection is associated with
increased amounts of free cholesterol in the cell mem-
brane, but also with reduced amounts of cholesterol esters
suggesting that prion infection alters cholesterol regula-
tion. The effects of prion infection on cholesterol balance
were reproduced in primary cortical neurons incubated
with exogenous PrPSc preparations.
Disturbing cholesterol metabolism within cells may have
profound effects on cell function. Although cholesterol is
a component of normal cell membranes, the amounts of
free cholesterol are increased between three- and five-fold
in specialised detergent-resistant micro-domains within
the plasma membrane that are commonly called lipid
rafts [8]. Such lipid rafts are also highly enriched in sphin-
golipids and gangliosides, and contain specific proteins
[9]. The raft-associated proteins include many proteins
attached to membranes via a glycosylphosphatidylinosi-
tol (GPI) anchor [10] including both PrPC and PrPSc [11].
In addition, cellular receptors for folate or the p75 neuro-
trophin receptor are found within rafts [12,13], as are
receptors for neurotransmitters including acetylcholine
[14] and gamma-aminobutyric acid [15]. Such domains
also contain components of signalling pathways includ-
ing the Src family tyrosine kinases [16], adenylyl cyclase
[17], the trimeric G-proteins [18] and cytoplasmic phos-
pholipase A2 (cPLA2) [19]. Lipid rafts act as membrane
platforms that concentrate molecules for cell signalling
[20] and changes in membrane cholesterol levels may
lead to abnormal cell signalling. As the neurotoxicity of
PrPSc was blocked by PLA2 inhibitors [21] the effects of
prion infection on PLA2 activity was examined. Here we
report increased activation (phosphorylation) of cPLA2 in
ScGT1 cells.
Results
Prion infection increased free cholesterol in neuronal cell 
lines
The amounts of protein and cholesterol in two prion-
infected neuronal cell lines (ScN2a and ScGT1 cells) were
compared to that of uninfected controls (N2a and GT1
cells). There were no significant differences in the
amounts of protein between infected and uninfected cells.
In contrast, the amounts of total cholesterol (a mixture of
free and esterified cholesterol) were significantly higher in
infected ScGT1 cells than in GT1 cells (542 ng cholesterol/
mg protein ± 44 versus 453 ± 72, n = 11, P = 0.004) (Table
1). More detailed analysis showed that the amounts of
free cholesterol within ScGT1 cells were 36% higher than
those in GT1 cells (500 ± 54 versus 368 ± 59, n = 11, P =
0.0003), while the amounts of esterified cholesterol were
50% less than in GT1 cells (42 ± 14 versus 85 ± 28, n = 11,
P = 0.0007). Similar results were obtained when ScN2a
and N2a cells were compared: amounts of free cholesterol
in ScN2a cells were 23% higher than in N2a cells (473 ±
41 versus 384 ± 37, n = 11, P = 0.0001), but the amounts
of esterified cholesterol were significantly lower than
those of N2a cells (52 ± 14 versus 87 ± 19, n = 11, P =
0.002). Thus, in both cell lines prion infection was associ-
Table 1: Prion infection increased the amounts of free cholesterol in neuronal cell lines. The amounts of total cholesterol, free 
cholesterol and esterified cholesterol (ng cholesterol/mg protein) in extracts from prion infected neuronal cells (ScN2a or ScGT1 
cells) compared with their non-infected counterparts (N2a or GT1 cells). Values shown are the mean ± SD from 11 samples.
Cholesterol (ng/mg protein)
Esterified
Total (mean ± SD) Free (mean ± SD) Mean ± SD Percentage
N2a 472 ± 47 384 ± 37 87 ± 19 18 ± 4
ScN2a 525 ± 34 473 ± 41 52 ± 14 10 ± 3
GT1 453 ± 72 368 ± 59 85 ± 28 19 ± 5
ScGT1 542 ± 44 500 ± 54 42 ± 14 8 ± 3Page 2 of 10
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terol esters and in the percentage of cholesterol that was
esterified (Table 1).
Brain-derived neurotrophic factor (BDNF) increased the
PrPSc content of ScGT1 cells [22]. Here we report that
treatment with BDNF, glial-derived neurotrophic factor
(GDNF) or retinoic acid also increased the PrPSc content
of ScGT1 cells, while treatment with nerve-growth factor
(NGF) did not (Table 2). The increased PrPSc content of
treated ScGT1 cells was accompanied by increased
amounts of free cholesterol. The free cholesterol content
of ScGT1 cells was significantly higher in cells treated with
BDNF (654 ng cholesterol/mg protein ± 61 versus 510 ±
48, n = 9, P = 0.003), GDNF (655 ± 59 versus 510 ± 48, n
= 9, P = 0.004) or retinoic acid (705 ± 83 versus 510 ± 48,
n = 9, P = 0.002) but not in cells treated with NGF (503 ±
72 versus 510 ± 48, n = 9, P = 0.64). None of the treat-
ments increased the cholesterol content of uninfected
GT1 cells showing that the increases in free cholesterol
were related to the PrPSc content of cells. To examine this
relationship further, ScGT1 cells were treated with varying
concentrations of GDNF and amounts of PrPSc and free
cholesterol were measured. A significant correlation coef-
ficient between the amounts of PrPSc and free cholesterol
was observed (Pearson correlation = 0.922); see Figure 1.
PrPSc increases the free cholesterol content of cortical 
neurons
As the above observations were on prion-infected neuro-
nal cell lines, we sought to determine whether PrPSc had
the same effect on non-transformed cells. Primary cortical
neurons were incubated with sub-lethal amounts of PrPSc,
or equivalent amounts of PrPC for 48 hours. The addition
of PrPSc increased the amounts of free cholesterol when
compared with untreated cells or cells treated with PrPC
(Figure 2). The amounts of free cholesterol were signifi-
cantly higher in neurons treated with 100 pg/ml PrPSc
than in untreated cells (704 ng/mg protein ± 73 versus
504 ± 58, n = 9, P = 0.0019). Similarly, the amounts of free
cholesterol were significantly higher in neurons treated
with 20 pg/ml PrPSc (632 ± 46 versus 504 ± 58, n = 9, P =
0.004). There was no significant difference in the amounts
of free cholesterol in untreated neurons and in neurons
incubated with 100 pg/ml PrPC (504 ± 58 versus 517 ± 46,
n = 9, P = 0.51).
Table 2: Correlation between PrPSc and free cholesterol content in ScGT1 cells. The amounts of PrPSc and free cholesterol in ScGT1 
and GT1 cells treated for 7 days with neurotrophic factors or retinoic acid as shown. Free cholesterol was measured in cell extracts 
using the Amplex Red cholesterol assay kit. Values shown are the mean ± SD from 9 samples. PrPSc content of cells significantly 
greater than those of untreated cells (P < 0.05) are indicated by * and free cholesterol content of cells significantly greater than those 
of untreated cells (P < 0.05) are indicated by #.
PrPSc (ng/ml) Free cholesterol (ng/mg protein)
ScGT1 GT1 ScGT1 GT1
Control 6.9 ± 0.2 - 510 ± 48 392 ± 44
10 ng/ml BDNF 15.2 ± 1.4* - 654 ± 61# 417 ± 43
10 ng/ml GDNF 14.2 ± 0.5* - 655 ± 59# 393 ± 32
10 ng/ml NGF 7.4 ± 1.7 - 503 ± 72 364 ± 45
100 nM retinoic acid 16.5 ± 2.1* - 705 ± 83# 440 ± 59
Correlation between the amounts of PrPSc and free choles-terol in ScGT1 cellsFigure 1
Correlation between the amounts of PrPSc and free 
cholesterol in ScGT1 cells. The amounts of PrPSc in GT1 
cells (❍) or ScGT1 cells (●) treated with varying amounts of 
GDNF for 7 days were plotted against the amounts of free 
cholesterol in the same cells (expressed as ng cholesterol/mg 
protein).Page 3 of 10
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esters but not free cholesterol in neurons
The possibility that prion infection stimulated cholesterol
synthesis was examined by comparing the effects of PrPSc
with those of increased cholesterol biosynthesis in cortical
neurons. Mevalonate is a precursor of cholesterol synthe-
sis that is a product of 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase, the rate-limiting step in
cholesterol synthesis [23]. Treatment with 100 µM meval-
onate significantly increased the amounts of total choles-
terol in neurons (562 ng cholesterol/mg protein ± 45
versus 482 ± 54, n = 9, P = 0.001); this increase consisted
primarily of cholesterol esters (96 ± 25 versus 42 ± 24, n =
9, P = 0.006) as the amounts of free cholesterol were
unchanged (466 ± 50 versus 440 ± 46, n = 9, P = 0.16).
Similar results were obtained in cells treated with 10 µM
cholesterol, which increased the amounts of cholesterol
esters (130 ± 55 versus 42 ± 24, n = 9, P = 0.001) but not
free cholesterol (446 ± 36 versus 440 ± 46, n = 9, P = 0.54);
see Figure 3. The percentage of cholesterol that was esteri-
fied in untreated cells (9% ± 4) was raised to 17% ± 5 in
neurons incubated with mevalonate, and 22% ± 8 in neu-
rons treated with cholesterol. The addition of mevalonate
or cholesterol did not affect the protein content of cell
extracts.
Prion infection increased activation of cPLA2 in neuronal 
cell lines
As lipid rafts act as platforms in which signalling com-
plexes assemble [24], the possibility that the altered com-
position of lipid rafts in prion-infected cells affected cell
signalling was examined. More specifically, as PLA2 was
required for prion formation [25], the amounts of acti-
vated cPLA2 in cells were examined. The amounts of acti-
vated (phosphorylated) cPLA2 in ScGT1 cells were greater
than those in GT1 cells (Figure 4A). The relationship
between activated cPLA2 and PrPSc was examined in ScGT1
cells treated with different neurotrophins or retinoic acid.
The increased PrPSc content of treated ScGT1 cells was
accompanied by increased amounts of activated cPLA2.
The amounts of activated cPLA2 in ScGT1 cells was signif-
icantly higher in cells treated with BDNF (514 units/ml ±
69 versus 395 ± 33, n = 9, P = 0.01), GDNF (542 ± 65 ver-
sus 395 ± 33, n = 9, P = 0.008) or retinoic acid (553 ± 79
Regulation of free cholesterol in cortical neuronsFig re 3
Regulation of free cholesterol in cortical neurons. The 
amounts of total cholesterol, free cholesterol and choles-
terol esters, all expressed as ng cholesterol/mg protein in 
cortical neurones treated for 24 hours in control medium 
(open bars), 100 µM mevalonate (black bars) or 50 µM cho-
lesterol (striped bars). Amounts of total cholesterol signifi-
cantly greater than those of untreated neurons (P < 0.05) are 
indicated with * and amounts of cholesterol esters signifi-
cantly greater than those of untreated neurons (P < 0.05) are 
indicated with #.
PrPSc causes a dose-dependent increase in the free choles-terol oncentration of cortical neuronsFigure 2
PrPSc causes a dose-dependent increase in the free 
cholesterol concentration of cortical neurons. The 
amounts of free cholesterol expressed as ng cholesterol/mg 
protein in cortical neurons treated for 48 hours with varying 
concentrations of PrPC (■) or PrPSc (). Amounts of free 
cholesterol significantly greater than those of untreated neu-
rons (P < 0.05) are indicated with *.Page 4 of 10
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with NGF (416 ± 46 versus 395 ± 33, n = 9, P = 0.41). In
contrast, none of these treatments significantly increased
the amounts of activated cPLA2 in GT1 cells showing that
increased activation of cPLA2 is related to the PrPSc content
of cells (Table 3). The relationship between cPLA2 and
PrPSc was examined further in ScGT1 cells treated with var-
ying concentrations of GDNF. The correlation coefficient
between the amounts of PrPSc in cells and the amounts of
activated cPLA2 was significant (Pearson correlation =
0.865); see Figure 4B.
Confirmation of increased PLA2 activity in ScGT1 cells was
provided by observations that the amounts of PGE2 pro-
duced by ScGT1 cells were significantly higher than that of
GT1 cells (318 pg/ml PGE2 ± 46 versus 134 ± 37, n = 6, P
= 0.000004). Similarly, the amounts of PGE2 produced by
ScN2a cells were significantly higher than that of N2a cells
(253 ± 40 versus 118 ± 13, n = 6, P = 0.0003). To ensure
that PGE2 was produced via the PLA2/cyclo-oxygenase
pathway, ScGT1 cells were treated with PLA2 or cyclo-oxy-
genase inhibitors. The addition of the PLA2 inhibitors
reduced PGE2 production in ScGT1 cells; treatment with 1µM AACOCF3 reduced PGE2 levels from 318 ± 46 to 98 ±
28, n = 6, P = 0.000002, while 1 µg/ml aristolochic acid
reduced PGE2 production to 124 ± 36, n = 6, P = 0.00001.
Cyclo-oxygenase inhibitors also reduced PGE2 produc-
tion, 100 nM acetyl-salicylic acid reduced PGE2 levels
from 318 ± 46 to 59 ± 34, n = 6, P = 0.0000005, and 500
nM ibuprofen reduced PGE2 production to 110 ± 40, n =
6, P = 0.00007.
Rafts containing PrPSc also contain cPLA2
Immunoprecipitation was used to determine whether
cPLA2 was associated with PrP-containing lipid rafts in
ScGT1 cells. Mab 4F2, which recognises both PrPC and
PrPSc, precipitated cPLA2 out of membrane extracts from
untreated ScGT1 cells. Two methods were used to show
that cPLA2 was associated with PrPSc rather than PrPC in
these ScGT1 cell extracts. First, immunoprecipitation with
mab IC18, which recognises PrPC but not PrPSc, did not
precipitate cPLA2 from ScGT1 cells. Second, immunopre-
cipitation with mab 4F2 precipitated cPLA2 from ScGT1
cells from which PrPC had been removed following treat-
ment with PI-PLC (Figure 5A). A mab to CD55, or an IgG2
isotype control, did not precipitate cPLA2 from ScGT1
cells. Next we examined the distribution of activated
cPLA2 within ScGT1 cells. The amounts of activated cPLA2
in whole cell extracts (100%) were compared with those
in membranes precipitated with mab 4F2 and to the
depleted membrane extract. Greater than 60% of activated
Table 3: Correlation between PrPSc and activated cPLA2 in ScGT1 cells. The amounts of PrPSc and activated cPLA2 (phosphorylated at 
serine 505) in ScGT1 and GT1 cells treated for 7 days with neurotrophic factors or retinoic acid as shown. Values shown are the mean 
± SD from 9 samples. PrPSc content of cells significantly greater than those of untreated cells (P < 0.05) are indicated by * and amounts 
of activated cPLA2 significantly greater than those of untreated cells (P < 0.05) are indicated by #.
PrPSc (ng/ml) Activated cPLA2 (units)
ScGT1 GT1 ScGT1 GT1
Control 6.9 ± 0.2 - 395 ± 33 100 ± 18
10 ng/ml BDNF 15.2 ± 1.4* - 514 ± 69# 102 ± 7
10 ng/ml GDNF 14.2 ± 0.5* - 542 ± 65# 109 ± 9
10 ng/ml NGF 7.4 ± 1.7 - 416 ± 46 98 ± 6
100 nM retinoic acid 16.5 ± 2.1* - 553 ± 79# 113 ± 13
Prion infection increases the amounts of activated cPLA2 in ScGT1 c llsFigure 4
Prion infection increases the amounts of activated 
cPLA2 in ScGT1 cells. (A) The amounts of activated cPLA2 
in cell extracts from 1 × 106 GT1 cells (open bars) or ScGT1 
cells (black bars). Values shown are the mean ± SD from 10 
samples. (B) The amounts of activated cPLA2 in ScGT1 cells 
treated with varying concentrations of GDNF for 7 days (●) 
were plotted against the amounts of PrPSc in the same cells.Page 5 of 10
(page number not for citation purposes)
BMC Biology 2008, 6:8 http://www.biomedcentral.com/1741-7007/6/8cPLA2 was found in the immunoprecipitated membrane
fraction (Figure 5B).
Discussion
The major goal of this study was to investigate the impact
of PrPSc on the biochemistry of cell membranes. The
amounts of total cholesterol in membranes were signifi-
cantly higher in prion-infected cell lines than in their
uninfected counterparts and there was a significant corre-
lation between amounts of cholesterol and PrPSc. More
specifically, prion infection was associated with a signifi-
cant increase in the amounts of free cholesterol. While
much of what is known about the role of cholesterol in
cell membranes is surmised from the changes in cells
brought about by cholesterol depletion, either from cho-
lesterol synthesis inhibitors or via cholesterol extraction,
little is known about how neurons respond when the cho-
lesterol content of membranes is increased.
How the presence of prions affects cholesterol levels
remains to be determined. A synthetic prion-derived pep-
tide activated HMG-CoA reductase suggesting a mecha-
nism by which prion infection increased cholesterol
production [26]. However, we were unable to replicate the
effects of prion infection in non-infected cells by stimulat-
ing cholesterol biosynthesis or by adding exogenous cho-
lesterol. The addition of mevalonate or cholesterol did
not increase the amounts of free cholesterol in cell mem-
branes; rather, they increased the amounts of cholesterol
esters. This contrasts with the situation in prion-infected
cells where the amounts of cholesterol esters were
reduced. Cholesterol in cells is found either as free choles-
terol in membranes or as cholesterol esters in cytoplasmic
droplets. A dynamic equilibrium between the pools of
free cholesterol and cholesterol esters is tightly controlled
by acyl-coenzyme A:cholesterol acyltransferase (ACAT),
an endoplasmic reticulum (ER)-resident enzyme that
catalyses the formation of cholesterol esters from choles-
terol and long-chain fatty acids [27]. In uninfected cells
excess free cholesterol activates ACAT resulting in
increased production of cholesterol esters. In these cells,
increased free cholesterol levels were only seen following
the addition of a combination of free cholesterol and an
ACAT inhibitor (data not shown).
The situation in prion-infected cells, where the increased
amounts of free cholesterol is accompanied by reduced
amounts of cholesterol esters, is unusual. The increase in
free cholesterol and the reduction of cholesterol esters in
prion-infected cells may be a result of direct inhibition of
ACAT or by sequestration of cholesterol in micro-environ-
ments that avoid ACAT. The amount of cholesterol in cell
membranes is partly determined by its fatty acid compo-
sition. The high incidence of saturated fatty acids attached
to sphingolipids, gangliosides and GPI-anchored proteins
allows tight molecular packing and increases the solubili-
sation of free cholesterol [28]. Thus, the formation of
PrPSc may have a direct effect on the composition of cell
membranes as the self-aggregation of PrPSc results in the
clustering of GPI anchors attached to PrPSc. The increased
density of saturated fatty acids within PrPSc-containing
micro-domains encourages the solubilisation of free cho-
lesterol and the remodelling of those membranes.
Increasing the free cholesterol content of membranes is
thought to reduce membrane fluidity and subsequently
affect the endocytosis and trafficking of proteins. There-
fore, the formation of PrPSc may alter conventional lipid
raft structure and the PrPC-protein interactions that occur
within lipid rafts. For example, PrPC has been reported to
bind to caveolin-1 [29] or N-CAM [30], proteins that
reside within lipid rafts. It is unclear whether these pro-
tein-protein interactions are affected following the con-
version of PrPC to PrPSc. The sequestration of free
Activated cPLA2 is associated with PrPSc in ScGT1 cellsFigure 5
Activated cPLA2 is associated with PrPSc in ScGT1 
cells. (A) Immunoblots showing amounts of cPLA2 immuno-
precipitated with antibodies to PrP (4F2 or IC18), CD55 or 
an isotype control (Iso) from untreated ScGT1 cells 
(Untreated) or from ScGT1 cells pre-treated with 0.2 units 
PI-PLC for 30 minutes (PI-PLC). (B) The amounts of activated 
cPLA2 (expressed as a percentage) in whole cell extracts 
from ScGT1 cells (open bars), from ScGT1 cell extracts 
depleted with the anti-PrP mab 4F2 (black bars) and in 4F2 
immunoprecipitates (IPT) from ScGT1 cell extracts (striped 
bars). Values shown are the mean ± SD from 10 samples.Page 6 of 10
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free cholesterol from other cellular pools where it helps to
stabilise the packing of sphingolipids, gangliosides and
raft-associated proteins in the membrane. This may affect
the function of such proteins. For example, free choles-
terol affects the formation and function of synapses [31].
Therefore, sequestration of cholesterol by PrPSc may affect
synaptic transmission, a hypothesis supported by obser-
vations that ScGT1 cells contain altered amounts of syn-
aptic proteins including synaptophysin [32] and that
synapse damage is seen during the early stages of experi-
mental prion diseases [6].
Cholesterol-dependent micro-domains are increasingly
implicated as platforms necessary for cell signalling [24]
and scrapie infections of neuronal cells are associated
with increased levels of Src kinase [33]. The activation of
PLA2 that is necessary for prion formation [25] is reduced
in cholesterol-depleted cells suggesting that this enzyme
may reside within a lipid raft [34]. Here we show that
ScGT1 cells contained four times as much activated cPLA2
as GT1 cells and there was a significant correlation
between amounts of activated cPLA2 and PrPSc. Immuno-
precipitation studies showed that activated cPLA2co-local-
ised with PrPSc-containing lipid rafts in ScGT1 cells.
Previous studies showed that cell activation results in the
translocation of cPLA2 to endoplasmic and plasma mem-
branes [35]. Our observations are consistent with the
hypothesis that prion infection stimulates the transloca-
tion of cPLA2 to lipid rafts containing PrPSc. The activation
of cPLA2 is associated with the production of prostagland-
ins and the amounts of PGE2 produced by ScGT1 cells
were significantly higher than that of GT1 cells. Our obser-
vation that pre-treatment of ScGT1 cells with PLA2 or
cyclo-oxygenase inhibitors reduced PGE2 production
showed that PGE2 was a valid measure of PLA2 activity in
these cells. These findings are consistent with reports of
increased PGE2 in murine scrapie [36] and raised levels of
PGE2 in the cerebrospinal fluid of patients with Creut-
zfeldt-Jakob disease [37].
Conclusion
We have demonstrated that the presence of PrPSc
increased the free cholesterol content of cell membranes.
The increased free cholesterol could not be replicated by
the stimulation of cholesterol synthesis or by the addition
of exogenous free cholesterol, which increased the
amounts of cholesterol esters. Our observations are con-
sistent with the hypothesis that the clustering of saturated
fatty acids, parts of the GPI anchors attached to PrPSc,
increased the amounts of free cholesterol solubilised
within the plasma membrane which increased membrane
rigidity. These changes in cell membranes could reduce
endocytosis and the recycling of cholesterol through the
ER where it is exposed to ACAT, consistent with reduced
cholesterol ester production in infected cells. The
increased amounts of free cholesterol in the plasma mem-
brane were associated with increased activation of the
PLA2 pathway that is necessary for PrPSc-mediated neuro-
toxicity. This is a rare example of an infective agent
increasing free cholesterol levels within cell membranes
and raises the possibility that disturbances in membrane




Prion-infected ScGT1 cells, from a murine hypothalamic
neuronal cell line infected by the Chandler scrapie isolate
and ScN2a neuroblastoma cells, were grown in Hams F12
medium supplemented with 2 mM glutamine, 2% foetal
calf serum (FCS) and standard antibiotics (100 U/ml pen-
icillin and 100 µg/ml streptomycin; Invitrogen, Paisley,
UK). Uninfected N2a or GT1 cells were used as non-
infected controls and grown in the same medium. To
determine the effect of neurotrophins or retinoic acid,
cells were plated at 1 × 105 cells/well in 6 well plates. Cells
were then grown with daily changes of media for 7 days.
Neuronal cultures
Primary cortical neurons were prepared from the brains of
mouse embryos (day 15.5) after mechanical dissociation,
cell sieving and isolation on histopaque (Sigma). Neuro-
nal precursors were plated (1,000,000 cells/well in 24 well
plates coated with 5 µg/ml poly-L-lysine) in Hams F12
containing 5% FCS for 2 hours. Cultures were shaken
(600 rpm for 5 minutes) and non-adherent cells removed
by two washes in phosphate buffered saline (PBS). Neu-
rons were grown in neurobasal medium (NBM) contain-
ing B27 components (Invitrogen) for 7 days and
subsequently incubated with test compounds. Immunola-
belling studies showed that after 7 days cultures contained
less than 5% glial cells (about 3% GFAP positive and less
than 1% MAC-1 positive cells).
Cell extracts
At the end of the treatment, cells were washed twice in PBS
and homogenised in an extraction buffer containing 10
mM Tris-HCl, 100 mM NaCl, 10 mM EDTA, 0.5% Noni-
det P-40, 0.5% sodium deoxycholate and 0.2% sodium
dodecyl sulphate (SDS) at 1 × 106 cells/ml. Mixed protease
inhibitors (AEBSF, Aprotinin, Leupeptin, Bestain, Pepsta-
tin A and E-46; from Sigma) were added to some cell
extracts. Membranes were prepared by repeated passage
with a Wheaton homogeniser; nuclei and large fragments
were removed by centrifugation (300 × g for 5 minutes).
To determine the amount of PrPSc in cells these superna-
tants were digested with 1 µg/ml proteinase K for 1 hour
at 37°C, digestion was stopped with mixed protease
inhibitors. The soluble material was heated to 95°C for 5Page 7 of 10
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nosorbent assay (ELISA).
PrP ELISA
The amount of PrP present in cell extracts was determined
in a sandwich ELISA using a capture mab (ICSM18 which
recognises amino acids 146 to 159 of murine PrP). Sam-
ples were applied and detected with biotinylated mab
ICSM35 (which recognises a region between amino acids
91 and 110). Biotinylated mab was detected using extravi-
din-alkaline phosphatase and 1 mg/ml 4-nitrophenyl
phosphate in a diethanolamine buffer (Sigma). Absorb-
ance was measured on a microplate reader at 450 nm and
the amount of PrP in cell extracts was calculated by refer-
ence to a standard curve of recombinant murine PrP (Pri-
onics, Zurich, Switzerland); its limit of detection was 0.05
ng/ml.
Cholesterol and protein content
Cellular cholesterol and protein content were determined
in cell extracts (1 × 106 cells/ml). Protein concentrations
were measured using a micro-BCA protein assay kit
(Pierce, Cramlington, UK). The amounts of cholesterol
were measured using the Amplex Red cholesterol assay kit
(Invitrogen), according to the manufacturer's instruc-
tions. Briefly, cholesterol is oxidised by cholesterol oxi-
dase to yield hydrogen peroxide and ketones. The
hydrogen peroxide reacts with 10-acetyl-3, 7-dihydroxy-
phenoxazine (Amplex Red reagent) to produce highly flu-
orescent resorufin, which is measured by excitation at 550
nm and emission detection at 590 nm. By performing the
assay in the presence or absence of cholesterol esterase (50
units/ml) the assay can also determine the amounts of
esterified cholesterol within samples.
Isolation of PrPSc/PrPC
PrPC was extracted from uninfected GT1 cells by immuno-
precipitation with a PrP-specific mab 4F2 and magnetic
protein G beads followed by reverse-phase chromatogra-
phy on a C18 column and a gradient of acetonitrile in
water and 0.1% triflouroacetic acid. PrPSc was extracted
from ScGT1 cells. Infectious cell extracts were digested
with 1 µg/ml proteinase K (37°C, 1 hour) and PrPSc was
precipitated with mab 4F2 and magnetic protein G beads.
PrPSc was subsequently isolated by reverse-phase chroma-
tography as above. The amounts of PrPSc/PrPC in different
fractions were quantified by a PrP-specific ELISA.
cPLA2 ELISA
The activation of cPLA2 is accompanied by phosphoryla-
tion of the 505 serine residue, which can be measured by
phospho-specific antibodies. The amounts of activated
cPLA2 in cell extracts were measured by a sandwich ELISA.
Nunc Maxisorb immunoplates were coated with 0.5 µg/
ml of mouse mab anti-cPLA2, clone CH-7 (Upstate, Mil-
ton Keynes, UK) in carbonate buffer for 1 hour and
blocked with 10% FCS. Samples were incubated for 1
hour at room temperature and the amounts of activated
cPLA2 were detected using a rabbit polyclonal anti-phos-
pho-cPLA2 (Cell Signalling Technology). Bound antibod-
ies were detected with biotinylated anti-rabbit IgG (Dako,
Ely, UK), extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenyl phosphate in a diethanolamine buffer.
Absorbance was measured at 450 nm and the amounts of
activated cPLA2 were calculated from a standard curve
using nonlinear regression. Samples were expressed as
'units cPLA2' where a measure of 100 units was defined as
the amount of cPLA2 in 1 × 106 untreated GT1 cells. A
standard curve was generated from this sample using
sequential log 2 dilutions (range 100 to 1.56 units/well).
PGE2 assay
The amounts of PGE2 produced by cells were determined
by using an enzyme-immunoassay kit (Amersham Bio-
tech, Amersham, UK) according to the manufacturer's
instructions. This assay is based on competition between
unlabelled PGE2 in the sample and a fixed amount of
labelled PGE2 for a PGE2 specific antibody. The detection
limit of this assay is 20 pg/ml.
Immunoprecipitations
Cells were washed in ice-cold PBS and incubated with
antibodies against decay accelerating factor (DAF; CD55,
mab BRIC 216, Bio-Products, Elstree, UK), PrP (mabs 4F2,
ICSM18) or an isotype control in ice-cold PBS containing
5% FCS. In some experiments ScGT1 cells were pre-
treated with 0.2 units/ml PI-PLC for 1 hour prior to
immunoprecipitation to remove surface PrPC. After 30
minutes cells were washed 5 times in ice-cold PBS and sol-
ubilised with 1% Triton × 100, 10 mM Tris-HCl, 100 mM
NaCl, 10 mM EDTA and protease inhibitors at 1 × 106
cells/ml for 1 hour at 4°C (this detergent solubilises the
normal cell membrane but does not affect lipid raft micro-
domains). Cell debris was removed from membrane prep-
arations by centrifugation (300 × g for 5 minutes) and the
supernatant was incubated with µMACS protein G
microbeads (10 µl/ml; Miltenyi Biotech, Bisley, UK) for
30 minutes. Protein G bound antibody complexes were
isolated using a µMACS magnetic system and standard
protocols (Miltenyi Biotech). For ELISA studies proteins
were eluted in 10 mM Tris-HCL, 150 mM NaCl, 10 mM
EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate,
0.2% SDS and mixed protease inhibitors at 1 × 106 cells/
ml. Other beads were boiled for 5 minutes in Laemmli
buffer (Bio-Rad) and subjected to electrophoresis on a
15% polyacrylamide gel. Proteins were transferred onto a
Hybond-P PVDF membrane (Amersham Biotech, UK) by
semi-dry blotting. Membranes were blocked using 10%
milk powder and cPLA2 was detected by mab CH-7.
Bound antibody was detected by a secondary anti-mousePage 8 of 10
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minescence kit (Amersham Biotech).
Reagents
Mevalonate and AACOCF3 were bought from Calbio-
chem, Nottingham, UK. Acetyl salicylic acid, ibuprofen,
MAPF, cholesterol, retinoic acid, BDNF, GDNF and NGF
were obtained from Sigma.
Statistical analysis
Comparison of treatment effects was carried out using
one- and two-way analysis of variance techniques as
appropriate. Post hoc comparisons of means were per-
formed as necessary. For all statistical tests significance
was set at the 5% level.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CB was responsible for the conception, planning and per-
formance of experiments and for writing this manuscript.
Both MT and AW contributed to the planning of experi-
ments, interpretation of results and the writing of the
manuscript.
Acknowledgements
We thank Dr Aviva Petrie for help in statistical analysis. This research was 
supported by the European Commission Framework Package 6 Network 
of Excellence 'NeuroPrion'.
References
1. Simons M, Keller P, Dichgans J, Schulz JB: Cholesterol and Alzhe-
imer's disease: is there a link?  Neurology 2001, 57(6):1089-1093.
2. Neuhaus O, Stuve O, Zamvil SS, Hartung HP: Evaluation of HMG-
CoA reductase inhibitors for multiple sclerosis: opportuni-
ties and obstacles.  CNS Drugs 2005, 19(10):833-41.
3. Fai Mok SW, Thelen KM, Riemer C, Bamme T, Gultner S, Lutjohann
D, Baier M: Simvastatin prolongs survival times in prion infec-
tions of the central nervous system.  Biochemical and Biophysical
Research Communications 2006, 348(2):697-702.
4. Prusiner SB: Prions.  Proc Natl Acad Sci USA 1998,
95(23):13363-13383.
5. Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz CP,
Scott H, Rawlins JN, Perry VH: Synaptic changes characterize
early behavioural signs in the ME7 model of murine prion
disease.  Eur J Neurosci 2003, 17(10):2147-2155.
6. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C,
Sayers AR, Brown DA, Fraser JR: Synapse loss associated with
abnormal PrP precedes neuronal degeneration in the
scrapie-infected murine hippocampus.  Neuropathol Appl Neuro-
biol 2000, 26(1):41-54.
7. Russelakis-Carneiro M, Hetz C, Maundrell K, Soto C: Prion replica-
tion alters the distribution of synaptophysin and caveolin 1 in
neuronal lipid rafts.  Am J Pathol 2004, 165(5):1839-1848.
8. Pike LJ: Lipid rafts: heterogeneity on the high seas.  Biochem J
2004, 378(Pt 2):281-292.
9. Ikonen E: Roles of lipid rafts in membrane transport.  Curr Opin
Cell Biol 2001, 13:470-477.
10. Varma R, Mayor S: GPI-anchored proteins are organized in
submicron domains at the cell surface.  Nature 1998,
394(6695):798-801.
11. Vey M, Pilkuhn S, Wille H, Nixon R, DeArmond SJ, Smart EJ, Ander-
son RG, Taraboulos A, Prusiner SB: Subcellular colocalization of
the cellular and scrapie prion proteins in caveolae-like mem-
branous domains.  Proc Natl Acad Sci USA 1996,
93(25):14945-14949.
12. Rothberg KG, Ying YS, Kamen BA, Anderson RG: Cholesterol con-
trols the clustering of the glycophospholipid-anchored mem-
brane receptor for 5-methyltetrahydrofolate.  J Cell Biol 1990,
111(6 Pt 2):2931-2938.
13. Bilderback TR, Grigsby RJ, Dobrowsky RT: Association of
p75(NTR) with caveolin and localization of neurotrophin-
induced sphingomyelin hydrolysis to caveolae.  Journal of Biolog-
ical Chemistry 1997, 272(16):10922-10927.
14. Baenziger JE, Morris ML, Darsaut TE, Ryan SE: Effect of membrane
lipid composition on the conformational equilibria of the nic-
otinic acetylcholine receptor.  Journal of Biological Chemistry 2000,
275(2):777-784.
15. Sooksawate T, Simmonds MA: Effects of membrane cholesterol
on the sensitivity of the GABA(A) receptor to GABA in
acutely dissociated rat hippocampal neurones.  Neuropharma-
cology 2001, 40(2):178-184.
16. Li S, Couet J, Lisanti MP: Src Tyrosine Kinases, Galpha Subunits,
and H-Ras Share a Common Membrane-anchored Scaffold-
ing Protein, Caveolin. Caveolin binding negatively regulates
the auto-activation of Src tyrosine kinases.  Journal of Biological
Chemistry 1996, 271(46):29182-29190.
17. Cooper DMF, Crossthwaite AJ: Higher-order organization and
regulation of adenylyl cyclases.  Trends in Pharmacological Sciences
2006, 27(8):426-431.
18. Oh P, Schnitzer JE: Segregation of heterotrimeric G proteins in
cell surface microdomains. G(q) binds caveolin to concen-
trate in caveolae, whereas G(i) and G(s) target lipid rafts by
default.  Mol Biol Cell 2001, 12(3):685-698.
19. Graziani AV, Bricko V, Carmignani M, Graier WF, Groschner K:
Cholesterol- and caveolin-rich membrane domains are
essential for phospholipase A(2)-dependent EDHF forma-
tion.  Cardiovasc Res 2004, 64(2):234-242.
20. Simons K, Toomre D: Lipid rafts and signal transduction.  Nat
Rev Mol Cell Biol 2000, 1(1):31-39.
21. Bate C, Salmona M, Williams A: The role of platelet activating
factor in prion and amyloid-β neurotoxicity.  Neuroreport 2004,
15:509-513.
22. Nordstrom EK, Luhr KM, Ibanez C, Kristensson K: Inhibitors of the
Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Path-
way Clear Prion-Infected Cells from PrPSc.  Journal of Neuro-
science 2005, 25(37):8451-8456.
23. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock
J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Sta-
pley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K,
Liesch J, Springer J: Mevinolin: a highly potent competitive
inhibitor of hydroxymethylglutaryl-coenzyme A reductase
and a cholesterol-lowering agent.  Proc Natl Acad Sci USA 1980,
77(7):3957-3961.
24. Simons K, Ikonen E: Functional rafts in cell membranes.  Nature
1997, 387:569-572.
25. Bate C, Reid S, Williams A: Phospholipase A2 inhibitors or plate-
let activating factor antagonists prevent prion replication.
Journal of Biological Chemistry 2004, 279:36405-36411.
26. Diomede L, Forloni G, Bugiani O, Tagliavini F, Salmona M: The prion
protein and cellular cholesterol homeostasis.  Neurobiology of
lipids 2002, 1(3):.
27. Chang TY, Chang aC, Cheng D: ACYL-COENZYME A:CHO-
LESTEROL ACYLTRANSFERASE.  Annual Review of Biochemis-
try 1997, 66(1):613-638.
28. Schroeder F, Gallegos AM, Atshaves BP, Storey SM, McIntosh AL,
Petrescu AD, Huang H, Starodub O, Chao H, Yang H, Frolov A, Kier
AB: Recent Advances in Membrane Microdomains: Rafts,
Caveolae, and Intracellular Cholesterol Trafficking.  Experi-
mental Biology and Medicine 2001, 226(10):873-890.
29. Massimino ML, Griffoni C, Spisni E, Toni M, Tomasi V: Involvement
of caveolae and caveolae-like domains in signalling, cell sur-
vival and angiogenesis.  Cell Signal 2002, 14(2):93-98.
30. Schmitt-Ulms G, Legname G, Baldwin MA, Ball HL, Bradon N, Bosque
PJ, Crossin KL, Edelman GM, DeArmond SJ, Cohen FE, Prusiner SB:
Binding of neural cell adhesion molecules (N-CAMs) to the
cellular prion protein.  J Mol Biol 2001, 314(5):1209-1225.Page 9 of 10
(page number not for citation purposes)
BMC Biology 2008, 6:8 http://www.biomedcentral.com/1741-7007/6/8Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
31. Pfrieger FW: Role of cholesterol in synapse formation and
function.  Biochimica et Biophysica Acta (BBA) – Biomembranes 2003,
1610(2):271-280.
32. Sandberg MK, Low P: Altered Interaction and Expression of
Proteins Involved in Neurosecretion in Scrapie-infected
GT1-1 Cells.  Journal of Biological Chemistry 2005, 280(2):1264-1271.
33. Gyllberg H, Lofgren K, Lindegren H, Bedecs K: Increased Src
kinase level results in increased protein tyrosine phosphor-
ylation in scrapie-infected neuronal cell lines.  FEBS Letters
2006, 580(11):2603-2608.
34. Bate C, Salmona M, Diomede L, Williams A: Squalestatin cures
prion-infected neurones and protects against prion neuro-
toxicity.  Journal of Biological Chemistry 2004, 279:14983-14990.
35. Liu J, Takano T, Papillon J, Khadir A, Cybulsky AV: Cytosolic phos-
pholipase A2-alpha associates with plasma membrane,
endoplasmic reticulum and nuclear membrane in glomeru-
lar epithelial cells.  Biochem J 2001, 353(Pt 1):79-90.
36. Williams AE, Van Dam AM, Man AHW, Berkenbosch F, Eikelenboom
P, Fraser H: Cytokines, prostaglandins and lipocortin-1 are
present in the brains of scrapie-infected mice.  Brain Res 1994,
654(2):200-206.
37. Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, Green AJ,
Knight R, Pocchiari M: Increased CSF levels of prostaglandin
E(2) in variant Creutzfeldt-Jakob disease.  Neurology 2002,
58(1):127-129.Page 10 of 10
(page number not for citation purposes)
